/PRNewswire/ Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new pooled analyses and post hoc results from the Phase 3 trials.
Allergan, an ABBVie company, today announced that it will present new pooled analyses and post hoc results from the Phase 3 trials of AGN-190584 an investigational novel treatment for presbyopia, at Academy 2021, the annual meeting of the American Academy of Optometry, November 3-6 . Presentations will include clinical results for near and intermediate vision, functional near vision, efficacy for post-LASIK .